Cargando…

The role of booster vaccination and ongoing viral evolution in seasonal circulation of SARS-CoV-2

Periodic resurgences of COVID-19 in the coming years can be expected, while public health interventions may be able to reduce their intensity. We used a transmission model to assess how the use of booster doses and non-pharmaceutical interventions (NPIs) amid ongoing pathogen evolution might influen...

Descripción completa

Detalles Bibliográficos
Autores principales: Kraay, A. N. M., Gallagher, M. E., Ge, Y., Han, P., Baker, J. M., Koelle, K., Handel, A., Lopman, B. A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Royal Society 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9448498/
https://www.ncbi.nlm.nih.gov/pubmed/36067790
http://dx.doi.org/10.1098/rsif.2022.0477
_version_ 1784784075710529536
author Kraay, A. N. M.
Gallagher, M. E.
Ge, Y.
Han, P.
Baker, J. M.
Koelle, K.
Handel, A.
Lopman, B. A.
author_facet Kraay, A. N. M.
Gallagher, M. E.
Ge, Y.
Han, P.
Baker, J. M.
Koelle, K.
Handel, A.
Lopman, B. A.
author_sort Kraay, A. N. M.
collection PubMed
description Periodic resurgences of COVID-19 in the coming years can be expected, while public health interventions may be able to reduce their intensity. We used a transmission model to assess how the use of booster doses and non-pharmaceutical interventions (NPIs) amid ongoing pathogen evolution might influence future transmission waves. We find that incidence is likely to increase as NPIs relax, with a second seasonally driven surge expected in autumn 2022. However, booster doses can greatly reduce the intensity of both waves and reduce cumulative deaths by 20% between 7 January 2022 and 7 January 2023. Reintroducing NPIs during the autumn as incidence begins to increase again could also be impactful. Combining boosters and NPIs results in a 30% decrease in cumulative deaths, with potential for greater impacts if variant-adapted boosters are used. Reintroducing these NPIs in autumn 2022 as transmission rates increase provides similar benefits to sustaining NPIs indefinitely (307 000 deaths with indefinite NPIs and boosters compared with 304 000 deaths with transient NPIs and boosters). If novel variants with increased transmissibility or immune escape emerge, deaths will be higher, but vaccination and NPIs are expected to remain effective tools to decrease both cumulative and peak health system burden, providing proportionally similar relative impacts.
format Online
Article
Text
id pubmed-9448498
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Royal Society
record_format MEDLINE/PubMed
spelling pubmed-94484982022-09-14 The role of booster vaccination and ongoing viral evolution in seasonal circulation of SARS-CoV-2 Kraay, A. N. M. Gallagher, M. E. Ge, Y. Han, P. Baker, J. M. Koelle, K. Handel, A. Lopman, B. A. J R Soc Interface Life Sciences–Engineering interface Periodic resurgences of COVID-19 in the coming years can be expected, while public health interventions may be able to reduce their intensity. We used a transmission model to assess how the use of booster doses and non-pharmaceutical interventions (NPIs) amid ongoing pathogen evolution might influence future transmission waves. We find that incidence is likely to increase as NPIs relax, with a second seasonally driven surge expected in autumn 2022. However, booster doses can greatly reduce the intensity of both waves and reduce cumulative deaths by 20% between 7 January 2022 and 7 January 2023. Reintroducing NPIs during the autumn as incidence begins to increase again could also be impactful. Combining boosters and NPIs results in a 30% decrease in cumulative deaths, with potential for greater impacts if variant-adapted boosters are used. Reintroducing these NPIs in autumn 2022 as transmission rates increase provides similar benefits to sustaining NPIs indefinitely (307 000 deaths with indefinite NPIs and boosters compared with 304 000 deaths with transient NPIs and boosters). If novel variants with increased transmissibility or immune escape emerge, deaths will be higher, but vaccination and NPIs are expected to remain effective tools to decrease both cumulative and peak health system burden, providing proportionally similar relative impacts. The Royal Society 2022-09-07 /pmc/articles/PMC9448498/ /pubmed/36067790 http://dx.doi.org/10.1098/rsif.2022.0477 Text en © 2022 The Authors. https://creativecommons.org/licenses/by/4.0/Published by the Royal Society under the terms of the Creative Commons Attribution License http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, provided the original author and source are credited.
spellingShingle Life Sciences–Engineering interface
Kraay, A. N. M.
Gallagher, M. E.
Ge, Y.
Han, P.
Baker, J. M.
Koelle, K.
Handel, A.
Lopman, B. A.
The role of booster vaccination and ongoing viral evolution in seasonal circulation of SARS-CoV-2
title The role of booster vaccination and ongoing viral evolution in seasonal circulation of SARS-CoV-2
title_full The role of booster vaccination and ongoing viral evolution in seasonal circulation of SARS-CoV-2
title_fullStr The role of booster vaccination and ongoing viral evolution in seasonal circulation of SARS-CoV-2
title_full_unstemmed The role of booster vaccination and ongoing viral evolution in seasonal circulation of SARS-CoV-2
title_short The role of booster vaccination and ongoing viral evolution in seasonal circulation of SARS-CoV-2
title_sort role of booster vaccination and ongoing viral evolution in seasonal circulation of sars-cov-2
topic Life Sciences–Engineering interface
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9448498/
https://www.ncbi.nlm.nih.gov/pubmed/36067790
http://dx.doi.org/10.1098/rsif.2022.0477
work_keys_str_mv AT kraayanm theroleofboostervaccinationandongoingviralevolutioninseasonalcirculationofsarscov2
AT gallagherme theroleofboostervaccinationandongoingviralevolutioninseasonalcirculationofsarscov2
AT gey theroleofboostervaccinationandongoingviralevolutioninseasonalcirculationofsarscov2
AT hanp theroleofboostervaccinationandongoingviralevolutioninseasonalcirculationofsarscov2
AT bakerjm theroleofboostervaccinationandongoingviralevolutioninseasonalcirculationofsarscov2
AT koellek theroleofboostervaccinationandongoingviralevolutioninseasonalcirculationofsarscov2
AT handela theroleofboostervaccinationandongoingviralevolutioninseasonalcirculationofsarscov2
AT lopmanba theroleofboostervaccinationandongoingviralevolutioninseasonalcirculationofsarscov2
AT kraayanm roleofboostervaccinationandongoingviralevolutioninseasonalcirculationofsarscov2
AT gallagherme roleofboostervaccinationandongoingviralevolutioninseasonalcirculationofsarscov2
AT gey roleofboostervaccinationandongoingviralevolutioninseasonalcirculationofsarscov2
AT hanp roleofboostervaccinationandongoingviralevolutioninseasonalcirculationofsarscov2
AT bakerjm roleofboostervaccinationandongoingviralevolutioninseasonalcirculationofsarscov2
AT koellek roleofboostervaccinationandongoingviralevolutioninseasonalcirculationofsarscov2
AT handela roleofboostervaccinationandongoingviralevolutioninseasonalcirculationofsarscov2
AT lopmanba roleofboostervaccinationandongoingviralevolutioninseasonalcirculationofsarscov2